Alveolar macrophages contribute to alveolar barrier dysfunction in ventilator-induced lung injury.
In patients requiring mechanical ventilation for acute lung injury or acute respiratory distress syndrome (ARDS), tidal volume reduction decreases mortality, but the mechanisms of the protective effect have not been fully explored. To test the hypothesis that alveolar macrophage activation is an early and critical event in the initiation of ventilator-induced lung injury (VILI), rats were ventilated with high tidal volume (HV(T)) for 10 min to 4 h. Alveolar macrophage counts in bronchoalveolar lavage (BAL) fluid decreased 45% by 20 min of HV(T) (P < 0.05) consistent with activation-associated adhesion. Depletion of alveolar macrophages in vivo with liposomal clodronate significantly decreased permeability and pulmonary edema following 4 h of HV(T) (P < 0.05). BAL fluid from rats exposed to 20 min of HV(T) increased nitric oxide synthase activity nearly threefold in naïve primary alveolar macrophages (P < 0.05) indicating that soluble factors present in the air spaces contribute to macrophage activation in VILI. Media from cocultures of alveolar epithelial cell monolayers and alveolar macrophages exposed to 30 min of stretch in vitro also significantly increased nitrite production in naïve macrophages (P < 0.05), but media from stretched alveolar epithelial cells or primary alveolar macrophages alone did not, suggesting alveolar epithelial cell-macrophage interaction was required for the subsequent macrophage activation observed. These data demonstrate that injurious mechanical ventilation rapidly activates alveolar macrophages and that alveolar macrophages play an important role in the initial pathogenesis of VILI.
Frank
James A
JA
University of California San Francisco, Departmnet of Medicine, San Francisco CA 94121, USA. james.frank@ucsf.edu
Wray
Charlie M
CM
McAuley
Danny F
DF
Schwendener
Reto
R
Matthay
Michael A
MA
D000818:Animals; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D004002:Clodronic Acid / Q000494:pharmacology; D004195:Disease Models, Animal; D006801:Humans; D008081:Liposomes / Q000008:administration & dosage; D016676:Macrophages, Alveolar / Q000187:drug effects / Q000502:physiology*; D011650:Pulmonary Alveoli / Q000502:physiology* / Q000503:physiopathology; D011654:Pulmonary Edema / Q000503:physiopathology*; D051381:Rats; D012128:Respiratory Distress Syndrome / Q000503:physiopathology*; D013990:Tidal Volume
D008081:Liposomes; D004002:Clodronic Acid